Fig. 2

The growth-inhibitory effect of rituximab was remarkably enhanced by plerixafor, in a drug concentration-dependent manner. The diffuse large B-cell lymphoma (DLBCL) cell lines RIVA (a) and FARAGE (b) were exposed to a two-fold serial dilution of the anti-CD20 antibody rituximab (4.17-66.67 μg/mL) and/or the CXCR4 antagonist plerixafor (208.33-3333.33 μM) for 48 h. When in combination, corresponding concentrations of the drugs were administered (i.e. C1 + C1, C2 + C2, and so forth). Blank-corrected absorbance values were obtained through MTS-based experiments. Data are presented as mean of a minimum of three technical replicates, with each individual replicate presented as a geometric symbol. PLX, plerixafor; RTX, rituximab